Transcranial Magnetic Stimulation Device Gets Drafted By Army
This article was originally published in The Gray Sheet
Executive Summary
Five months into the launch of Neuronetics' NeuroStar transcranial magnetic stimulation (TMS) therapy device to treat depression, a Walter Reed Army Medical Center psychiatrist is learning the ins and outs of using the technology on patients
You may also be interested in...
Device Companies Look Far and Wide for New Capital
The global recession that struck last September drove many device investors into hiding. This left a barren financial landscape for device companies to subsist on. But some are finding the funds they need, and they're sharing their survival stories.
Device Companies Look Far and Wide for New Capital
The global recession that struck last September drove many device investors into hiding. This left a barren financial landscape for device companies to subsist on. But some are finding the funds they need, and they're sharing their survival stories.
Neuronetics Overcomes Negative Panel Review To Earn Clearance For NeuroStar
FDA cleared Neuronetics' NeuroStar transcranial magnetic stimulation system for drug-resistant depression, despite a negative advisory panel review, based on a pivotal study subset analysis